| Literature DB >> 36090029 |
Xiaolin Liang1, Simeng Zhang1, Difei Zhang1,2,3, Liang Hu1,4, Yu Peng1,2, Yuan Xu1,2, Haijing Hou1,2,3, Chuan Zou1,2,3, Xusheng Liu1,2,3, Yang Chen1,3, Fuhua Lu1,2,3.
Abstract
Background: IgA nephropathy (IgAN) is the most common type of glomerulonephritis in Asia. Its pathogenesis involves higher expression of galactose-deficient IgA1 (Gd-IgA1) and dysregulated intestinal mucosal immunity. The objective of this study was to explore whether specific gut microbiota and associated enzymes affect Gd-IgA1 in IgAN.Entities:
Keywords: Flavonifractor plautii; galactose-deficient IgA1; gut microbiota; immunoglobulin a nephropathy; metagenomics sequencing.; α-N-acetyl-galactosaminidase; α-galactosidase
Year: 2022 PMID: 36090029 PMCID: PMC9449366 DOI: 10.3389/fmolb.2022.970723
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
Frequency list of lifestyle and dietary habits in IgAN patients and healthy controls.
| Variables | IgAN ( | HC ( |
|
|---|---|---|---|
| Lifestyle | |||
| Actual hours of sleep | 0.106 | ||
| <6h | 0 | 4 (20%) | |
| 6–9h | 19 (95%) | 15 (75%) | |
| >9h | 1 (5%) | 1 (5%) | |
| Sleep quality | 0.365 | ||
| Excellent | 6 (30%) | 10 (50%) | |
| Good | 11 (55%) | 7 (35%) | |
| Poor | 3 (15%) | 3 (15%) | |
| Dietary habits | |||
| Refined carbohydrates | 0.194 | ||
| Always | 14 (70%) | 15 (75%) | |
| Usually | 3 (15%) | 5 (25%) | |
| Sometimes | 3 (15%) | 0 | |
| Never | 0 | 0 | |
| Red meat | 0.432 | ||
| Always | 1 (5%) | 2 (10%) | |
| Usually | 13 (65%) | 8 (40%) | |
| Sometimes | 4 (20%) | 5 (25%) | |
| Never | 2 (10%) | 5 (25%) | |
| White meat | 0.065 | ||
| Always | 0 | 6 (30%) | |
| Usually | 10 (50%) | 7 (35%) | |
| Sometimes | 7 (35%) | 5 (25%) | |
| Never | 3 (15%) | 2 (10%) | |
| Vegetables | 0.001 | ||
| Always | 14 (70%) | 4 (20%) | |
| Usually | 5 (25%) | 16 (80%) | |
| Sometimes | 1 (5%) | 0 | |
| Never | 0 | 0 | |
| Fruits | 0.371 | ||
| Always | 4 (20%) | 7 (35%) | |
| Usually | 7 (35%) | 8 (40%) | |
| Sometimes | 8 (40%) | 3 (15%) | |
| Never | 1 (5%) | 2 (10%) | |
| Probiotic drink | 1.000 | ||
| Always | 0 | 0 | |
| Usually | 2 (10%) | 3 (15%) | |
| Sometimes | 7 (35%) | 6 (30%) | |
| Never | 11 (55%) | 11 (55%) | |
| Taste preferences | 0.693 | ||
| Bland | 12 (60%) | 9 (45%) | |
| Salty | 5 (25%) | 8 (40%) | |
| Spicy | 3 (15%) | 3 (15%) | |
Note: The p value is significant if <0.05.
Legend: Always = everyday; usually = 4–6 days per week; sometimes = 1–3 days per week; never = 0–1 day per week.
Baseline characteristics of the IgAN patients.
| Characteristics | IgAN ( |
|---|---|
| Mean ± SD or n (%) or n | |
| Demographoc | |
| Age (years) | 38.5 ± 8.7 |
| Male gender (%) | 10(50%) |
| Height (m) | 1.6 ± 0.1 |
| Weight (kg) | 57.9 ± 9.9 |
| BMI (kg/m2) | 22.3 ± 3.7 |
| SBP (mmHg) | 125.9 ± 19.4 |
| DBP (mmHg) | 79.6 ± 11.9 |
| MAP (mmHg) | 95.0 ± 13.7 |
| Smoker (%) | 0 |
| Alcohol user (%) | 8 (38.10%) |
| Comorbidities | |
| Hypertension | 5(25%) |
| Hyperlipemia | 6(30%) |
| Diabetes | 0 |
| Hyperuricemia | 6(30%) |
| Chronic Gastritis | 1(5%) |
| Hepatic steatosis | 4(20%) |
| Laboratory values | |
| Hb (g/L) | 131.3 ± 10.7 |
| TP (g/L) | 63.9 ± 8.0 |
| ALB (g/L) | 38.2 ± 6.5 |
| GLB (g/L) | 25.8 ± 3.2 |
| FBG (mmol/L) | 5.8 ± 2.2 |
| sCr (μmol/L) | 97.0 ± 39.2 |
| Urea (mmol/L) | 5.5 ± 1.5 |
| UA (μmol/L) | 420.0 ± 76.5 |
| eGFR (ml/min/1.73㎡) | 84.0 ± 30.0 |
| TG (mmol/L) | 1.8 ± 1.5 |
| TC (mmol/L) | 5.4 ± 1.8 |
| HDL-C (mmol/L) | 1.2 ± 0.4 |
| LDL-C (mmol/L) | 3.7 ± 1.6 |
| hsCRP (mg/L) | 1.9 ± 2.4 |
| IgA (g/L) | 3.2 ± 1.0 |
| IgG (g/L) | 10.2 ± 2.3 |
| IgM (g/L) | 1.1 ± 0.6 |
| C3 (g/L) | 1.1 ± 0.2 |
| C4 (g/L) | 0.2 ± 0.1 |
| CH50 (g/L) | 30.2 ± 7.9 |
| U-RBC (cells/μL) | 95.4 ± 142.5 |
| 24h U-PRO (g/24h) | 1.7 ± 2.7 |
| uPCR (g/g) | 1.9 ± 4.4 |
| D-RBC/U-RBC | 0.8 ± 0.2 |
| kapU (mg/L) | 71.0 ± 142.7 |
| lamU (mg/L) | 44.4 ± 99.4 |
| IgGU (mg/L) | 85.1 ± 86.3 |
| β2-Mg (mg/L) | 0.9 ± 1.8 |
| ALBU (mg/L) | 2226.1 ± 4784.1 |
| α1-MU (mg/L) | 26.2 ± 38.0 |
| α2-MU (mg/L) | 4.6 ± 5.2 |
| TrfU (mg/L) | 53.6 ± 42.1 |
| Histological findings, n | |
| M0/M1 | 1/19 |
| E0/E1 | 17/3 |
| S0/1S | 14/6 |
| T0/T1/T2 | 16/3/1 |
| C0/C1/C2 | 6/13/1 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; Hb, hemoglobin; TP, total protein; ALB, albumin; GLB, globulin; FBG, fasting blood glucose; sCr, serum creatinine; UA, uric acid; eGFR, estimated glomerular filtration rate; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; C3, complement three; C4, complement 4; CH50, total complement activity; U-RBC, urine red blood cells; 24 h U-PRO, 24-hour urine protein; uPCR, urine protein creatinine ratio; kapU, urine immunoglobulin kap; lamU, urine immunoglobulin lam; IgGU, urine immunoglobulin G; β2-Mg, urine β2-microglobulin; ALBU, albuminuria; α1-MU, urine α1 microglobulin; α2-MU, urine α2 macroglobulin; TrfU, urine Transferrin; M, mesangial hypercellularity; E, endocapillary hypercellularity; S, segmental sclerosis; T, tubular atrophy/interstitial fibrosis; C crescents.
FIGURE 1Community Profiling analysis showing differential relative abundances of fecal microbiota in IgAN patients and HCs. (A) Microbiome composition of the two groups at the genus level. (B) Microbiome composition of the two groups at the species level. (C) Relative abundance of the top 10 species in each sample.
FIGURE 2Rarefaction curves and comparison of diversity indexes between IgAN patients and HCs. (A) Rarefaction curves of patients with IgAN and HCs at the species level. The sequencing depth was judged to be sufficient as the curve tended to be flat. The detection rate of the microbial community was almost flat, revealing a reasonable sequencing volume that could cover most species. (B) α-diversity indexes in IgAN patients and HCs (observed, diversity Shannon and Simpson indexes depict diversity; pielou, evenness Simpson and Gini depict evenness; camargo, dbp and core abundance depict dominance). (C) PcoA for β-diversity analysis. Green and red represent different samples from the two groups. The structure and composition of the gut microbiota in patients with IgAN were not significantly different from those of HCs. (D) Venn diagram. There were 71 species shared between the two groups, while 13 species were specific to HCs and 7 species were specific to IgAN patients.
FIGURE 3Analysis of Enterotypes between IgAN patients and HCs. (A) A PCA plot indicating that enterotypes driven by Bacteroides and Prevotella were dominants in IgAN and HCs groups, respectively. (B) Frequency of enterotypes in both groups. (C) Abundance of Bacteroides and Prevotella between the two groups showed an opposite trend.
FIGURE 4Gut microbiota differences from phylum to species between patients with IgAN and HCs. (A) Microbiome biomarkers were identified using a logarithmic linear discriminant analysis (LDA) effect size (LefSe) threshold >4.0. (B) HeatTree for clustering analysis. Red indicates a significant increase in abundance in IgAN patients compared to the HCs, while blue depicts the opposite. (C) Co-occurrence network analysis of stool microbiota using Pearson’s correlation coefficient. A node represents a species. The node size indicates the level of abundance. Color scale indicates the proportion of bacterium in the two groups separately. Red depicts IgAN patients while green depicts HCs. Connecting lines indicate the strength of the relationship. (D) Correlation coefficient rank at the genus level. Red denotes positive associations in IgAN patients, while blue denotes negative associations. The legend on the right indicates the abundance of the bacterium in both groups, with red indicating high and blue indicating low abundance (c = class; o = order; f = family; g = genera; s = species).
FIGURE 5Heatmaps showing correlations between gut microbiota species and IgAN clinical parameters. The intensity of the color indicates the r value (correlation). The red color represents a positive score, and the blue color represents a negative one. *p <0.05 and **p <0.01.
FIGURE 6Enrichment of functional pathways of differential bacteria between IgAN patients and HCs. (A) The distribution of LDA values for different pathways in IgAN and HCs samples. (B) Relative contribution of gut microbes to pathways IgAN patients. (C) Relative contribution of gut microbes to pathways in HCs samples. Enrichment was defined as p < 0.05, q <0.1 and LDA>3.0.
FIGURE 7The enrichment of active enzymes and their corresponding specific bacteria. (A) Enzymes enriched by gut flora in IgAN patients and HCs. (B) The relative abundance of β-galactosidase, β-N-acetylhexosaminidase, α-galactosidase and α-N-acetylgalactosaminidase between the IgAN group and HCs. (C) The stratification of various bacteria for β-galactosidase, β-N-acetylhexosaminidase, α-galactosidase and α-N-acetylgalactosaminidase.